Affinia

Affinia Therapeutics Receives EMA Orphan Designation for Gene Therapy AFTX-201 in BAG3 Cardiomyopathy

Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class…

Read MoreAffinia Therapeutics Receives EMA Orphan Designation for Gene Therapy AFTX-201 in BAG3 Cardiomyopathy